The study also confirmed that inhibition of miR-15 can save cardiomyocytes from death during myocardial infarction.
MiRagen Therapeutics president and CEO William S Marshall said that the data indicates that antimiR-15 family therapy may induce a protective effect in response to ischemic cardiac injury by reducing infarct size and cardiac remodeling and by enhancing cardiac function.
"Combined with our findings showing that antimiR-15 therapy may also stimulate cardiomyocyte regeneration, these results suggest that inhibition of the miR-15 family represents a compelling dual mechanism approach to disease treatment in an area of significant unmet medical need," Marshall added.
The previous study also proved that inhibition of miR-15 could stimulate cardiomyogenesis.